Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
-
Julien Taïeb, Olivier Bouche, Thierry André, Karine Le Malicot, Pierre Laurent-Puig, et al.. Avelumab vs Standard Second-Line Chemotherapy in Patients with Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. JAMA oncology, 2023, 9 (10), ⟨10.1001/jamaoncol.2023.2761⟩. ⟨hal-04322943⟩
-
-
-
-
-
Amandine Desette, Pierre-Olivier Guichet, Sheik Emambux, Konstantin Masliantsev, Ulrich Cortes, et al.. Deciphering Brain Metastasis Stem Cell Properties From Colorectal Cancer Highlights Specific Stemness Signature and Shared Molecular Features. Cellular and Molecular Gastroenterology and Hepatology, 2023, 16 (5), pp.757-782. ⟨10.1016/j.jcmgh.2023.07.008⟩. ⟨hal-04302791⟩
-
Mots clés
EGFR
Cancer bronchique non à petites cellules
Advanced
Adjuvant
Cancer
BRAFV600E
Prevention
BRAFV600E mutation
Advanced melanoma
BRAF V600E
Allelic imbalance
Immunohistochemistry
Beta-catenin
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
BRAF V600-mutation
Prognostic
Radiofrequency ablation
Trametinib
Abdominal pain
Follow-up
Wnt
Anti-PD-1
Anti-PD1
C797S
Anti-PD1 blockade
Targeted therapy
ALK
Biomarkers
Circulating cell-free DNA
Biliopancreatic diversion
Locally advanced
BRAF
Mesenchymal stromal cells
Metastatic
AZD9291
Immunotherapy
Diagnosis
AML
Sonic Hedgehog
Surgical excision
Abscopal effect
Nivolumab
Immunomodulation
Plasma
CARMN
Colorectal carcinoma
Adverse events
Lung adenocarcinoma
ALK rearrangement
Androgen insensitivity
Resistance
Staging
Non-small cell lung cancer
Polyomavirus
Anti-PD-1 antibody
Antibody-drug conjugate
Survival
Chemotherapy
BRAFV600-mutant melanoma
Cemiplimab
Brain Metastases
Crizotinib
2-chlorodeoxyadenosine
Adjuvant therapy
Invasive cutaneous squamous cell carcinoma
Circulating tumor DNA
Bone marrow niche
Gastric bypass
Cutaneous squamous cell carcinoma
ADN tumoral circulant
Bariatric surgery
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Radiotherapy
Osimertinib
Children
Antineoplastic agents
Immune checkpoint inhibitor
TNM classification
Colorectal cancer
Acute generalized exanthematous pustulosis
Dabrafenib
Metastatic cSCC
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Melanoma
Langerhans cell histiocytosis
Anti-CTLA-4
Biomarker
Adjuvant FOLFOX
ACTH
Anti-Tumor pharmacology
Molecular targeted therapies
Histiocytosis
Chemoresistance
Treatment
Safety
Systemic therapy
Merkel cell carcinoma
Colon cancer
Body mass index
Prognosis